Recommendation...Men with advanced or metastatic, hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer should be offered endocrine therapy as first-line therapy except in cases of visceral crisis or rapidly progressive disease. Options include tamoxifen, an aromatase inhibitor with a gonadotropin-releasing hormone agent, and fulvestrant.